Aviva PLC Trims Position in STAAR Surgical (NASDAQ:STAA)

Aviva PLC lessened its stake in STAAR Surgical (NASDAQ:STAA – Get Rating) by 2.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,715 shares of the medical instruments supplier’s stock after selling 448 shares during the quarter. Aviva PLC’s holdings in STAAR Surgical were worth $860,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC purchased a new position in STAAR Surgical during the 3rd quarter valued at about $41,000. Dfpg Investments LLC increased its position in STAAR Surgical by 4.7% during the 4th quarter. Dfpg Investments LLC now owns 6,289 shares of the medical instruments supplier’s stock valued at $431,000 after purchasing an additional 281 shares during the period. Quantamental Technologies LLC increased its position in STAAR Surgical by 36.3% during the 3rd quarter. Quantamental Technologies LLC now owns 6,453 shares of the medical instruments supplier’s stock valued at $455,000 after purchasing an additional 1,718 shares during the period. Trexquant Investment LP increased its position in STAAR Surgical by 722.3% during the 3rd quarter. Trexquant Investment LP now owns 43,334 shares of the medical instruments supplier’s stock valued at $3,057,000 after purchasing an additional 38,064 shares during the period. Finally, Legacy Advisors LLC purchased a new position in STAAR Surgical during the 3rd quarter valued at about $214,000. Hedge funds and other institutional investors own 97.55% of the company’s stock.

STAAR Surgical Stock Down 1.0 %

STAA stock opened at $63.29 on Monday. The firm has a 50 day moving average of $65.02 and a 200 day moving average of $63.21. The stock has a market capitalization of $3.06 billion, a PE ratio of 98.89 and a beta of 1.23. STAAR Surgical has a 52 week low of $46.35 and a 52 week high of $112.27.

STAAR Surgical (NASDAQ:STAA – Get Rating) last released its earnings results on Tuesday, February 21st. The medical instruments supplier reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). STAAR Surgical had a return on equity of 9.85% and a net margin of 10.81%. The company had revenue of $64.04 million during the quarter, compared to analyst estimates of $64.37 million. On average, equities research analysts expect that STAAR Surgical will post 0.57 earnings per share for the current year.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, CTO Keith Holliday sold 823 shares of STAAR Surgical stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $61.97, for a total transaction of $51,001.31. Following the completion of the sale, the chief technology officer now directly owns 27,633 shares in the company, valued at approximately $1,712,417.01. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Stephens reissued an “overweight” rating and set a $85.00 target price on shares of STAAR Surgical in a research report on Wednesday, February 22nd. StockNews.com started coverage on shares of STAAR Surgical in a report on Thursday. They issued a “hold” rating on the stock. Canaccord Genuity Group raised their price target on shares of STAAR Surgical from $79.00 to $80.00 and gave the company a “buy” rating in a report on Monday, January 30th. Piper Sandler started coverage on shares of STAAR Surgical in a report on Monday, April 17th. They issued a “neutral” rating and a $65.00 price target on the stock. Finally, Benchmark lowered their price target on shares of STAAR Surgical from $78.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, February 1st. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, STAAR Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $81.18.

About STAAR Surgical

(Get Rating)

STAAR Surgical Co engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens.